Cancer and heart commitment for AXA PPP

AXA PPP healthcare is enhancing its support for policyholders affected by cancer or by heart disease. With immediate effect, the medical insurer is providing full cover for licensed cancer drugs – without time or monetary limits, and for as long as the patient needs them – on its standard level of cover for individuals* and SME groups.**

9 January 2012

Posted in Product

For cancer treatment, AXA PPP is also waiving any monetary limits that may apply to out-patient tests and consultations.

In addition, AXA PPP is extending its freephone Dedicated Nurse service, which it currently offers to members undergoing treatment for cancer, to support members who are diagnosed with a heart condition - providing them and their families with access to a dedicated nurse who can discuss their queries and concerns, bringing understanding and reassurance at what can be a difficult and uncertain time.

For those who've been treated for cancer or undergone heart surgery,*** there is the peace of mind of a 'no time limit' approach to paying for follow-up tests and consultations to monitor their progress and recovery over the longer term.

Further features of AXA PPP's enhanced cover for cancer include:

Benefit for experimental cancer drug treatment when undertaken as part of an ethical clinical trial.
Hospice benefit: a charitable donation of £100 per night for care provided in a registered hospice or for hospice care provided at home - without a time or monetary limit.
Additional expenses support: including £150 towards wigs and up to £5,000 to cover the cost of external prostheses such as eyes or limbs.

We want our members to be confident that, if they need treatment for cancer or a heart problem, we're committed to supporting them - not just by settling their medical bills but also by helping them through our Dedicated Nurse service and by providing additional benefits that can help to make life a little easier when they need it most.

Fergus Craig, Commercial Director at AXA UK PPP

These enhancements apply both to new customers and to existing AXA PPP members with immediate effect.

AXA PPP's large corporate and healthcare trust customers will continue to have the option to choose their level of cover for treatment of cancer (ranging from no cover to enhanced levels of cover).

For more information visit AXAPPPhealthcare.co.uk

Media contacts

Legal notes

About the AXA Group

The AXA Group is a worldwide leader in insurance and asset management, with 160,000 employees serving 108 million clients in 57 countries. In 2019, IFRS revenues amounted to Euro 103.5 billion and underlying earnings to Euro 6.5 billion. AXA had Euro 974 billion in assets under management as of December 31, 2019.

In the UK & Ireland, AXA operates through a number of business units including: AXA Insurance, AXA Health and AXA Ireland. AXA UK & Ireland employs around 10,000 staff.

The AXA ordinary share is listed on compartment A of Euronext Paris under the ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA). AXA’s American Depository Share is also quoted on the OTC QX platform under the ticker symbol AXAHY.

The AXA Group is included in the main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD.

It is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment.

For more information see AXA's Corporate Responsibility strategy and SRI ratings.

Important legal information and cautionary statements concerning forward-looking statements

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in such forward looking statements. Please refer to Part 4 - “Risk Factors and Risk Management” of AXA’s 2018 Registration Document, for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.